tbuckley/cabot-search huggingface dataset:
Prenatal Cannabis Use Before and During the COVID-19 Pandemic
Authors: Howard L. Minkoff, Jeffrey L. Ecker
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Electrophysiology of Acute Myocardial Ischemia
Authors: H. Fozzard
Journal: Annual Review of Medicine (1985)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Workshops of the eighth international brain–computer interface meeting: BCIs: the next frontier
Authors: Jane E. Huggins, Dean Krusienski, Mariska J. Vansteensel, Davide Valeriani, Antonia Thelen, Sergey Stavisky, James J.S. Norton, Anton Nijholt, Gernot Müller-Putz, Nataliya Kosmyna, Louis Korczowski, Christoph Kapeller, Christian Herff, Sebastian Halder, Christoph Guger, Moritz Grosse-Wentrup, Robert Gaunt, Aliceson Nicole Dusang, Pierre Clisson, Ricardo Chavarriaga, Charles W. Anderson, Brendan Allison, Tetiana Aksenova, Erik Aarnoutse
Journal: Brain-Computer Interfaces (2022)

The Eighth International Brain–Computer Interface (BCI) Meeting was held June 7–9, 2021 in a virtual format. The conference continued the BCI Meeting series' interactive nature with 21 workshops covering the breadth of topics in BCI (also called brain–machine interface) research. Some workshops provided detailed examinations of methods, hardware, or processes. Others focused on BCI applications or user groups. Several workshops continued consensus building efforts designed to create BCI standards and improve comparisons between studies and the potential for meta-analysis and large multi-site clinical trials. Ethical and translational considerations were the primary topic for some workshops or an important secondary consideration for others. The range of BCI applications continues to expand, with more workshops focusing on approaches that can extend beyond the needs of those with physical impairments. This paper summarizes each workshop, provides background information and references for further study, summarizes discussions, and describes the resulting conclusion, challenges, or initiatives.
<i>AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care</i>
Authors: Patrick A. Williams, Sayyed Kaleem Zaidi, Rajarshi Sengupta
Journal: Clinical Cancer Research (2022)

The coronavirus disease 2019 , now entering its third year, has led to major disruptions to economic stability, health care, and scientific research across the globe.To address the negative impact of COVID-19 on the cancer care continuum as well as the broader interruptions caused by the pandemic to the field of cancer research, the American Association for Cancer Research launched several initiatives.The AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care (https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/) is one of these initiatives that presents current evidence on the burden of COVID-19 among patients with cancer and highlights the challenges as well as future opportunities created by the pandemic in cancer research and patient care.The report concludes with a Call to Action that provides policy guidance on how to better serve the cancer community in the future.In this article, we highlight key findings of the report including how COVID-19 disrupted cancer care for patients; how cancer researchers fueled progress in fighting the pandemic; how interruptions caused by COVID-19 impacted cancer research more broadly; and how regulatory changes necessitated by to the pandemic led to a revolution in telehealth adoption and clinical trial design.
A randomized controlled trial of academic group practice
Authors: Richard F. Afable
Journal: JAMA (1987)

<h3>To the Editor.—</h3> Goldberg et al<sup>1</sup>must be commended for their study of alternative methods of organizing the teaching medical clinic. Those of us who are actively involved in supervising teaching clinics know that organization is generally an exception to the rule. Attempts to expedite patient care and satisfaction while maintaining resident participation and education often meet with obstacles. Cleveland General Hospital's system of "firms" within a group practice seems to be a feasible and apparently successful alternative to traditional methods. However, I feel the authors have failed to comment on another important reason to change to a group practice. The major challenge facing medical education in the ambulatory setting is financial: who pays? Good will and philanthropy on the part of hospitals have given way to diagnosis related groups and discount medicine. Thus, the medicine clinic must become more self-sufficient. Many institutions have organized their clinic supervisory staff
Current Comment
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neuron-derived neuropeptide Y fine-tunes the splenic immune responses
Authors: Jinsong Yu, Ke Xiao, Xiaohua Chen, Lulu Deng, Lu Zhang, Yue Li, Anran Gao, Junjun Gao, Chengchao Wu, Xinmei Yang, Qiudi Zhou, Jian Yang, Chenyu Bao, Jiaji Jiao, Sheng Cheng, Zhiqing Guo, Weize Xu, Xiaojian Cao, Zheng Guo, Jinxia Dai, Ji Hu, Zhenfang Fu, Gang Cao
Journal: Neuron (2022)
Platinum-based drugs for cancer therapy and anti-tumor strategies
Authors: Chunyu Zhang, Chao Xu, Xueyun Gao, Qingqiang Yao
Journal: Theranostics (2022)

Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer.However, the side effects of platinum drugs, such as lack of selectivity, high systemic toxicity, and drug resistance, seriously limit their clinical application.With advancements in nanotechnology and chemical synthesis, Pt-based anti-cancer drugs have made great progress in cancer therapy in recent years.Many strategies relied on the anti-cancer mechanism similar to cisplatin and achieved some success by modifying existing platinum drugs.Pt-based nanodrugs, such as platinum nanoclusters, have novel anti-cancer mechanisms and great potential in tumor-targeted therapy and have shown promising results in clinical application.In this review, we systematically explored the development of first-line platinum chemotherapy drugs in the clinic and their anti-cancer mechanisms.We also summarize the progress of Pt-based anti-cancer drug application in cancer therapy, emphasizing their modification to enhance the anti-tumor effect.Finally, we address challenges faced by platinum chemotherapy drugs, especially Pt nanocluster-based nanodrugs, in cancer treatment.The new platinum drugs and their targeted modifications undoubtedly provide a promising prospect for improving the current anti-cancer treatments.
ONE THOUSAND CASES OF PNEUMONIA TREATED IN HOSPITAL.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Rock
Authors: Jack Coulehan
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Richard von Volkmann (1830-1889), proponent of listerism in Germany
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts Pt.34
Authors: Brian Beger, Charles Barranco, Geert Cauwenbergh, Mr Beger, Vera Van De Velde, Mr Barranco, Lori Whitley, Elizabeth Dugan, Shmuel Shoham, Thomas Nigra, Alfons Mirada, Jaime Nasarre
Journal: Journal of the American Academy of Dermatology (2006)
How can WHO transform its approach to social determinants of health?
Authors: Unni Gopinathan, Kent Buse
Journal: BMJ (2022)

The social determinants of health are the circumstances in which people are born, grow, live, work, and age, and these are shaped by the inequitable distribution of power, money, and other resources in society. 1 Differences in income or unequal exposure to environmental risks contribute to unfair health outcomes within and between populations, something the covid-19 pandemic has brought into sharp focus.
Workforce Caring for Cancer Survivors in the United States: Estimates and Projections of Use
Authors: Angela B Mariotto, Lindsey Enewold, Helen Parsons, Christopher A Zeruto, K Robin Yabroff, Deborah K Mayer
Journal: JNCI Journal of the National Cancer Institute (2022)

This study aims to quantify the extent and diversity of the cancer care workforce, beyond medical oncologists, to inform future demand because the number of cancer survivors is expected to grow in the United States.Surveillance, Epidemiology, and End Results-Medicare data were used to evaluate health-care use of cancer survivors diagnosed between 2000 and 2014, enrolled in fee-for-service Medicare Parts A and B, and 65 years or older in 2008-2015. We calculated percentage of cancer survivors who saw each clinician specialty and their average annual number of visits in each phase of care. We projected the national number of individuals receiving care and number of annual visits by clinician specialty and phase of care through 2040.Cancer survivors had higher care use in the first year after diagnosis and last year of life phases. During the initial year after cancer diagnosis, most survivors were seen for cancer-related care by a medical oncologist (59.1%), primary care provider (55.9%), and/or other cancer-treating physicians (42.2%). The percentage of survivors with cancer-related visits to each specialty declined after the first year after diagnosis, plateauing after year 6-7. However, at 10 or more years after diagnosis, approximately 20% of cancer survivors had visits to medical oncologists and an average of 4 visits a year.Cancer survivors had higher care use in the first year after diagnosis and last year of life. High levels of care use across specialties in all phases of care have important implications for models of survivorship care coordination and workforce planning.
Accurate identification of circRNA landscape and complexity reveals their pivotal roles in human oligodendroglia differentiation
Authors: Yangping Li, Feng Wang, Peng Teng, Li Ku, Li Chen, Yue Feng, Bing Yao
Journal: Genome biology (2022)

Circular RNAs (circRNAs), a novel class of poorly conserved non-coding RNAs that regulate gene expression, are highly enriched in the human brain. Despite increasing discoveries of circRNA function in human neurons, the circRNA landscape and function in developing human oligodendroglia, the myelinating cells that govern neuronal conductance, remains unexplored. Meanwhile, improved experimental and computational tools for the accurate identification of circRNAs are needed.We adopt a published experimental approach for circRNA enrichment and develop CARP (CircRNA identification using A-tailing RNase R approach and Pseudo-reference alignment), a comprehensive 21-module computational framework for accurate circRNA identification and quantification. Using CARP, we identify developmentally programmed human oligodendroglia circRNA landscapes in the HOG oligodendroglioma cell line, distinct from neuronal circRNA landscapes. Numerous circRNAs display oligodendroglia-specific regulation upon differentiation, among which a subclass is regulated independently from their parental mRNAs. We find that circRNA flanking introns often contain cis-regulatory elements for RNA editing and are predicted to bind differentiation-regulated splicing factors. In addition, we discover novel oligodendroglia-specific circRNAs that are predicted to sponge microRNAs, which co-operatively promote oligodendroglia development. Furthermore, we identify circRNA clusters derived from differentiation-regulated alternative circularization events within the same gene, each containing a common circular exon, achieving additive sponging effects that promote human oligodendroglia differentiation.Our results reveal dynamic regulation of human oligodendroglia circRNA landscapes during early differentiation and suggest critical roles of the circRNA-miRNA-mRNA axis in advancing human oligodendroglia development.
End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB
Authors: Da Huang, Di Wu, Peng Wang, Yongli Wang, Wei Yuan, Danqing Hu, Junjian Hu, Yaqi Wang, Ran Tao, Fang Xiao, Xiaoping Zhang, Xiaojing Wang, Meifang Han, Xiaoping Luo, Weiming Yan, Qin Ning
Journal: Journal of Hepatology (2022)

Functional cure can be sustained in a proportion of patients with chronic hepatitis B (CHB) who lose hepatitis B surface antigen (HBsAg) after pegylated interferon alpha (Peg-IFN-ɑ)-based treatment. In this study, we aimed to identify biomarkers associated with a durable functional cure and to dissect potential immunological mechanisms.Of 257 nucleos(t)ide analogue-suppressed patients with CHB in the ANCHOR study, 80 patients randomly assigned to 96-week Peg-IFN-α-based therapy with 24-week off-treatment follow-up were included in this parallel study. Virologic and immunological biomarkers were examined dynamically. A response was defined as HBsAg loss or hepatitis B surface antibody (HBsAb) appearance at the end of treatment (EOT). Sustained response (SR) or durable functional cure was defined as sustained HBsAg loss with or without the appearance of HBsAb at the end of follow-up (EOF).Thirty-six (45.0%) out of 80 patients achieved a response at EOT; 58.3% (21/36) of responders maintained SR at EOF. Quantitative hepatitis B core-related antigen (qHBcrAg) and HBsAb at EOT were associated with SR, with AUROCs of 0.697 (0.512-0.882, p = 0.047) and 0.744 (0.573-0.915, p = 0.013), respectively. A combination of HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT had a positive predictive value of 100% for SR with an AUROC of 0.822 (0.684-0.961, p = 0.001). These patients showed maintained proportions of HBV envelope-specific CD8+T and B cells, a markedly increased proportion of T follicular helper cells after Peg-IFN-ɑ discontinuation, and significantly higher proportions of HBV polymerase-specific CD8+T and CD86+CD19+B cells at EOF.Lower HBcrAg and higher HBsAb levels at EOT were associated with sustained cellular and humoral immune responses. They can be used to identify patients likely to achieve durable functional cure post Peg-IFN-based therapy.NCT02327416 LAY SUMMARY: Functional cure can be sustained in a proportion of patients with chronic hepatitis B after pegylated interferon alpha-based treatment. However, predicting who will achieve durable functional cure remains challenging. Herein, we show that low levels of hepatitis B core-related antigen and higher levels of hepatitis B surface antibodies at the end of treatment are linked to immunological responses and are associated with durable functional cure.
The Campaign Against Rheumatism
Journal: Annals of the Rheumatic Diseases (1948)

P.-S.Hench calls attention to the vastness of the problem in America and this country and the neces- sity for more support, both from the Governments and from the public if this scourge is to be tackled adequately." In every country the same findings have been made: (1) rheumatic diseases outrank all others as a cause of chronic morbidity; (2) rheumatic disease annually involves each country in great expense; (3) adequate facilities for the care of most rheumatic patients are non-existent."Hench quotes staggering figures for the United States and compares their prospects with those of others, " for example for 680,000 tuberculous patients there are available about 100,000 free beds and 100,000,000 dollars annually for care and research but for 6,850,000 rheumatic patients there are available only about 200 free beds and 20(,000 dollars annually for care and research.In other words, although there are ten times as many rheumatic as tuberculous patients, the latter have available 500 times more beds and money.Thus the tuberculous patient, happily thereby a vanishing race, receives 5,000 times as much attention as the non-vanishing rheumatic."He points out that a survey of voluntary health agencies in America discloses the astonishing paradox that " the greater the need the less the public support" but considers that this is due simply to the fact that the public has not been sufficiently informed or aroused (sae Table ).
Depletion of the apical endosome in response to viruses and bacterial toxins provides cell-autonomous host defense at mucosal surfaces
Authors: Keiko Maeda, Nicholas C. Zachos, Megan H. Orzalli, Stefanie S. Schmieder, Denis Chang, Katlynn Bugda Gwilt, Michele Doucet, Nicholas W. Baetz, Sun Lee, Sue E. Crawford, Mary K. Estes, Jonathan C. Kagan, Jerrold R. Turner, Wayne I. Lencer
Journal: Cell Host & Microbe (2022)
The Disorders of Digestion in Infancy and Childhood.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal